Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Kim Hejny"'
Autor:
Mohammed S. I. Mansour, Kim Hejny, Felicia Johansson, Joudy Mufti, Ante Vidis, Ulrich Mager, Annika Dejmek, Tomas Seidal, Hans Brunnström
Publikováno v:
Diagnostics, Vol 11, Iss 10, p 1927 (2021)
PD-L1 expression assessed by immunohistochemical staining is used for the selection of immunotherapy in non-small cell lung cancer (NSCLC). Appropriate validation of PD-L1 expression in cytology specimens is important as cytology is often the only di
Externí odkaz:
https://doaj.org/article/c81548ac3a6f41cd9d86278aac33a7a7
Autor:
Maria Planck, Lena Tran, Despoina Violidaki, Mohammed S. I. Mansour, Tomas Seidal, Benjamin Holmgren, Annika Dejmek, Kim Hejny, Katalin Dobra, Kajsa Ericson Lindquist, Rikard Mohlin, Hans Brunnström, Ulrich Mager
Publikováno v:
Acta Cytol
Introduction: Programmed death-ligand 1 (PD-L1) expression is used for treatment prediction in non-small cell lung cancer (NSCLC). While cytology may be the only available material in the routine clinical setting, testing in clinical trials has mainl
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4b730b752be77e0e94f5157abf0cc3c6
https://doi.org/10.1159/000517078
https://doi.org/10.1159/000517078
Autor:
Brunnström, Mohammed S. I. Mansour, Karina Malmros, Ulrich Mager, Kajsa Ericson Lindquist, Kim Hejny, Benjamin Holmgren, Tomas Seidal, Annika Dejmek, Katalin Dobra, Maria Planck, Hans
Publikováno v:
International Journal of Molecular Sciences; Volume 23; Issue 9; Pages: 4517
Immune checkpoint inhibitors (ICI) targeting programmed cell death-1 or its ligand (PD-L1) have improved outcomes in non-small cell lung cancer (NSCLC). High tumor PD-L1 expression, detected by immunohistochemistry (IHC) typically on formalin-fixed p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=multidiscipl::10e243b1fc6ffe9ebb39d154d29df4d8
Autor:
Mohammed S I, Mansour, Karina, Malmros, Ulrich, Mager, Kajsa, Ericson Lindquist, Kim, Hejny, Benjamin, Holmgren, Tomas, Seidal, Annika, Dejmek, Katalin, Dobra, Maria, Planck, Hans, Brunnström
Publikováno v:
International journal of molecular sciences. 23(9)
Immune checkpoint inhibitors (ICI) targeting programmed cell death-1 or its ligand (PD-L1) have improved outcomes in non-small cell lung cancer (NSCLC). High tumor PD-L1 expression, detected by immunohistochemistry (IHC) typically on formalin-fixed p
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fd7848056da6fac306e38a60f7923df6
https://pubmed.ncbi.nlm.nih.gov/35562908
https://pubmed.ncbi.nlm.nih.gov/35562908